Review





Similar Products

mtpub1 mtdmi2 mld lrr n a medicago trunca tula symbiotic signaling vernié  (Medicago)
86
Medicago mtpub1 mtdmi2 mld lrr n a medicago trunca tula symbiotic signaling vernié
Mtpub1 Mtdmi2 Mld Lrr N A Medicago Trunca Tula Symbiotic Signaling Vernié, supplied by Medicago, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mtpub1 mtdmi2 mld lrr n a medicago trunca tula symbiotic signaling vernié/product/Medicago
Average 86 stars, based on 1 article reviews
mtpub1 mtdmi2 mld lrr n a medicago trunca tula symbiotic signaling vernié - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
medicinal leaf dataset mld  (Kaggle Inc)
86
Kaggle Inc medicinal leaf dataset mld
Medicinal Leaf Dataset Mld, supplied by Kaggle Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/medicinal leaf dataset mld/product/Kaggle Inc
Average 86 stars, based on 1 article reviews
medicinal leaf dataset mld - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
tandem mld lrr rlk pair  (Medicago)
86
Medicago tandem mld lrr rlk pair
Tandem Mld Lrr Rlk Pair, supplied by Medicago, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tandem mld lrr rlk pair/product/Medicago
Average 86 stars, based on 1 article reviews
tandem mld lrr rlk pair - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
trials in mld  (Takeda)
86
Takeda trials in mld
Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with <t>MLD</t> onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues <t>in</t> <t>MLD:</t> Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.
Trials In Mld, supplied by Takeda, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trials in mld/product/Takeda
Average 86 stars, based on 1 article reviews
trials in mld - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
mld initiative disease registry  (Disease Registry)
90
Disease Registry mld initiative disease registry
Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with <t>MLD</t> onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues <t>in</t> <t>MLD:</t> Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.
Mld Initiative Disease Registry, supplied by Disease Registry, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mld initiative disease registry/product/Disease Registry
Average 90 stars, based on 1 article reviews
mld initiative disease registry - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mld and other leukodystrophies clinical trials  (Bluebird Bio)
90
Bluebird Bio mld and other leukodystrophies clinical trials
Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with <t>MLD</t> onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues <t>in</t> <t>MLD:</t> Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.
Mld And Other Leukodystrophies Clinical Trials, supplied by Bluebird Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mld and other leukodystrophies clinical trials/product/Bluebird Bio
Average 90 stars, based on 1 article reviews
mld and other leukodystrophies clinical trials - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mld and other leukodystrophies  (Takeda)
90
Takeda mld and other leukodystrophies
Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with <t>MLD</t> onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues <t>in</t> <t>MLD:</t> Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.
Mld And Other Leukodystrophies, supplied by Takeda, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mld and other leukodystrophies/product/Takeda
Average 90 stars, based on 1 article reviews
mld and other leukodystrophies - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mld mouse model  (Sanofi)
90
Sanofi mld mouse model
Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with <t>MLD</t> onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues <t>in</t> <t>MLD:</t> Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.
Mld Mouse Model, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mld mouse model/product/Sanofi
Average 90 stars, based on 1 article reviews
mld mouse model - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mld gene therapy atidarsagene autotemcel  (Glaxo Smith)
90
Glaxo Smith mld gene therapy atidarsagene autotemcel
Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with <t>MLD</t> onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues <t>in</t> <t>MLD:</t> Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.
Mld Gene Therapy Atidarsagene Autotemcel, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mld gene therapy atidarsagene autotemcel/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
mld gene therapy atidarsagene autotemcel - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with MLD onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues in MLD: Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.

Journal: Journal of Inherited Metabolic Disease

Article Title: ARSA Variants Associated With Cognitive Decline and Long‐Term Preservation of Motor Function in Metachromatic Leukodystrophy

doi: 10.1002/jimd.70072

Figure Lengend Snippet: Distribution and severity of ARSA variants identified in this study and location of affected amino acid residues. (A) Donut chart illustrating the proportion of patients with MLD onset types within the c.256C>T, p.(Arg86Trp), c.257G>A, p.(Arg86Gln), and c.542T>G, p.(Ile181Ser) groups. The distribution of the second ARSA variants per MLD onset type is shown across these groups. Functional severity of the second ARSA variants is indicated based on Trinidad et al., with known severe variants in red, known mild or moderate variants in black, and variants with unknown functional severity in blue. Asterisks (*) denote conflicting interpretations of functional severity. (B) 3D model of the ASA monomer (Protein Data Bank 1AUK, visualized using the PyMOL Molecular Graphics System, Version 3.0.3 Schrödinger LLC ) depicting the locations of amino acid residue Arg86 (blue, affected by the c.256C>T and c.257G>A variants) and Ile181 (yellow, affected by the c.542T>G variant) and three other commonly affected amino acid residues in MLD: Pro428, commonly affected in patients with late‐juvenile and adult MLD, is orange. Gly124 and Gly310, affected in patients with late‐infantile MLD, are red. Amino acid residues forming the active center of ASA are highlighted in teal. Helices, β‐sheets, and loops are represented as ribbons, arrows, and threads, respectively.

Article Snippet: Nicole I. Wolf is advisor and/or co‐investigator for trials in MLD (Shire/Takeda, Orchard, Evidera) and other leukodystrophies (Ionis, PassageBio, Vigil Neuro), with all payments to the institution.

Techniques: Functional Assay, Residue, Variant Assay